Tag: Alzheimer’s disease

Adios Aduhelm

The controversial and never-proven-effective drug to treat Alzheimer's disease, aducanumab (Aduhelm) has been discontinued.

/ February 15, 2024

FDA Approves Leqembi for Alzheimer’s

FDA upgrades Leqembi for AD from accelerated to traditional approval based on latest clinical data.

/ July 12, 2023

AI as a Diagnostic Tool

Using AI systems for pattern recognition in early diagnosis of dementia shows the potential of this tool.

/ May 17, 2023
Alzheimer's Disease

Congress criticizes the FDA and the Aduhelm approval

A Congressional report on the approval of the Alzheimer's drug Aduhelm identified serious concerns about the FDA's processes

/ February 16, 2023

Another Controversial Alzheimer’s Drug

A new treatment for Alzheimer's Disease is promising, but we're not there yet.

/ November 30, 2022

Can supplements improve memory and cognition?

Can you reduce the risk of cognitive decline with dietary supplements?

/ September 1, 2022

Fraud, Scientific Rigor, and Alzheimer’s Research

A stunning case of possible fraud in Alzheimer's research reinforces the need for scientific rigor at every level.

/ August 10, 2022

COVID Associated With Neurodegenerative Disorders

COVID infection has been associated with an increased risk of neurodegenerative and neurovascular disease - another reason to keep our eye on this serious illness.

/ June 29, 2022
Alzheimer's Disease

Medicare and Medicaid place restrictions on new Alzheimer’s drug, Aduhelm (aducanumab)

An important decision has been made about a controversial new drug to treat Alzheimer's disease.

/ January 20, 2022

Poor Science Reporting and Premature Enthusiasm

Press releases often outpace the data. Here are some examples of over-enthusiastic reporting on extremely preliminary research.

/ December 21, 2021